Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SPHK2 | Q9NRA0 | 8/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 8/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3895146 | 0.80 | POLB (0.42) | POLBL3MBTL1SPHK2SPHK1PARP1 | |
| SCHEMBL22034423 | 0.80 | POLB (0.42) | POLBL3MBTL1SPHK2SPHK1PARP1 | |
| SCHEMBL19989685 | 0.80 | POLB (0.42) | POLBL3MBTL1SPHK2SPHK1PARP1 | |
| SCHEMBL10699421 | 0.80 | POLB (0.42) | POLBL3MBTL1SPHK2SPHK1PARP1 | |
| SCHEMBL1414126 | 0.80 | POLB (0.42) | POLBL3MBTL1SPHK2SPHK1PARP1 | |
| SCHEMBL14940906 | 0.79 | TERT (0.40) | POLBL3MBTL1LMNAALDH1A1 | |
| SCHEMBL14067026 | 0.76 | — | — | |
| SCHEMBL2268870 | 0.76 | — | — | |
| SCHEMBL5554539 | 0.74 | POLB (0.37) | POLBL3MBTL1SPHK2SPHK1KMT2A | |
| SCHEMBL3893332 | 0.74 | CFB (0.38) | POLBL3MBTL1SPHK2SPHK1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309192-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC, | 2014-10-16 | — | — | US | claimed |
| EP-2776407-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2014-09-17 | — | — | EP | claimed |
| WO-2013070657-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-05-16 | — | — | WO | claimed |
| US-20140309192-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC, | 2014-10-16 | — | — | US | disclosed |
| EP-2776407-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013070657-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309192-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | MRGPRX1, MRGPRX2, AGTR1 | POLB 4595/4885L3MBTL1 4183/4885SPHK2 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.